Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, discusses three important studies focusing on newer therapies for patients with recurrent platinum-sensitive, platinum-agnostic, and advanced recurrent ovarian cancers (Abstracts 6003, 6004, and 6005).
Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, explores whether autologous transplantation, in patients with relapsed diffuse large B-cell lymphoma who achieve...
Lakshmi Nayak, MD, of Dana-Farber Cancer Institute, reviews two key abstracts on newly diagnosed primary central nervous system lymphoma and treatment with whole-brain radiot...
Howard A. Burris III, MD, FACP, FASCO, talks about some of the reports of research developments he is looking forward to and how future conferences could incorporate virtual ...
Egbert F. Smit, MD, PhD, of the Netherlands Cancer Institute, discusses interim results from the DESTINY-Lung01 trial of fam-trastuzumab deruxtecan in patients with HER2<...
Nancy U. Lin, MD, of Dana-Farber Cancer Institute, discusses the HER2CLIMB study of patients with previously treated HER2-positive metastatic breast cancer that had metastasi...
